Patent: 8,231,895
✉ Email this page to a colleague
Summary for Patent: 8,231,895
Title: | Targeted delivery to human diseases and disorders |
Abstract: | The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders. |
Inventor(s): | de Almeida Moreira; Joao Nuno Sereno (Coimbra, PT), Caldeira de Moura; Vera L cia Dantas Nunes (Coimbra, PT), de Magalhaes Simoes; Sergio Paulo (Coimbra, PT), Pedroso de Lima; Maria da Conceicao Monteiro (Coimbra, PT) |
Assignee: | Universidade de Coimbra (Coimbra, PT) Centro de Neurociencias e Biologia Celular (Coimbra, PT) |
Application Number: | 12/153,649 |
Patent Claims: | see list of patent claims |
Details for Patent 8,231,895
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |